We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+11.18%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$3.07B
AUM Growth
+$226M
Cap. Flow
-$6.05M
Cap. Flow %
-0.2%
Top 10 Hldgs %
24.71%
Holding
329
New
29
Increased
101
Reduced
173
Closed
14

Sector Composition

Rank Sector Weight
1 Healthcare 25.97%
2 Technology 23.54%
3 Industrials 17.51%
4 Consumer Discretionary 11.34%
5 Communication Services 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PCRX icon
26
Pacira BioSciences
PCRX
$997M
$38.5M 1.26%
549,596
-4,338
-0.8% -$310K
RDWR icon
27
Radware
RDWR
$1.19B
$36.2M 1.18%
1,387,311
+202,559
+17% +$5.54M
ON icon
28
ON Semiconductor
ON
$31.6B
$34.6M 1.13%
831,522
-263,075
-24% -$10.1M
IAA
29
DELISTED
IAA, Inc. Common Stock
IAA
$34.6M 1.13%
626,911
-10,442
-2% -$620K
MEDP icon
30
Medpace
MEDP
$16.5B
$33.1M 1.08%
202,043
+6,059
+3% +$927K
STRA icon
31
Strategic Education
STRA
$1.92B
$31.7M 1.03%
344,979
-29,408
-8% -$2.64M
FATE icon
32
Fate Therapeutics
FATE
$326M
$31.7M 1.03%
384,362
-2,965
-0.8% -$284K
RVNC
33
DELISTED
Revance Therapeutics, Inc.
RVNC
$30.9M 1.01%
1,106,547
-14,605
-1% -$404K
OZK icon
34
Bank OZK
OZK
$5.61B
$30.7M 1%
751,740
-6,661
-0.9% -$262K
PGTI
35
DELISTED
PGT, Inc.
PGTI
$28.2M 0.92%
1,116,072
+6,340
+0.6% +$149K
SUPN icon
36
Supernus Pharmaceuticals
SUPN
$2.77B
$27.1M 0.88%
1,035,089
-2,289
-0.2% -$64K
WLDN icon
37
Willdan Group
WLDN
$1.3B
$25.6M 0.83%
623,854
+33,619
+6% +$1.55M
AERI
38
DELISTED
Aerie Pharmaceuticals
AERI
$25M 0.81%
1,398,066
+29,058
+2% +$502K
DFIN icon
39
Donnelley Financial Solutions
DFIN
$1.16B
$24.9M 0.81%
+895,339
New +$20.7M
PTC icon
40
PTC
PTC
$16B
$24.8M 0.81%
180,506
-7,702
-4% -$1.03M
ECHO
41
DELISTED
Echo Global Logistics, Inc.
ECHO
$24.8M 0.81%
788,055
+5,468
+0.7% +$159K
AGM icon
42
Federal Agricultural Mortgage
AGM
$2.56B
$24.7M 0.8%
245,056
+1,660
+0.7% +$143K
ETSY icon
43
Etsy
ETSY
$7.85B
$24M 0.78%
118,841
-234,468
-66% -$49.1M
IOVA icon
44
Iovance Biotherapeutics
IOVA
$2.87B
$22.4M 0.73%
705,927
-5,471
-0.8% -$227K
COLL icon
45
Collegium Pharmaceutical
COLL
$956M
$21.9M 0.72%
925,828
+4,903
+0.5% +$116K
LKQ icon
46
LKQ Corp
LKQ
$6.29B
$21.6M 0.71%
510,943
+30,945
+6% +$1.22M
ALBO
47
DELISTED
Albireo Pharma Inc
ALBO
$20.2M 0.66%
572,899
+315,527
+123% +$11.6M
ARNA
48
DELISTED
Arena Pharmaceuticals Inc
ARNA
$20M 0.65%
287,959
-1,973
-0.7% -$152K
QLYS icon
49
Qualys
QLYS
$6.35B
$19.9M 0.65%
190,391
-1,079
-0.6% -$121K
CNTY icon
50
Century Casinos
CNTY
$34M
$18.6M 0.61%
1,813,312
+38,117
+2% +$318K

Similar funds

Rice Hall James & Associates's Q1 2021 Portfolio in Review

As of Q1 2021, Rice Hall James & Associates held 329 positions worth $3.07B, up 7.9% from $2.84B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rice Hall James & Associates's Q1 2021 filing shows 29 new, 101 increased, 173 reduced and 14 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 264,558 shares worth $18.1M. The largest sale was Etsy, an estimated $49.1M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 26% a quarter earlier, followed by Technology and Industrials.

  • Rice Hall James & Associates's largest Q1 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 264,558 shares worth $18.1M.
  • Rice Hall James & Associates added most to Stride in Q1 2021, an estimated $15.5M increase.
  • Rice Hall James & Associates's biggest Q1 2021 reduction was Etsy, cutting an estimated $49.1M.
  • Rice Hall James & Associates fully exited Grand Canyon Education in Q1 2021, selling an estimated $6.68M.
  • Rice Hall James & Associates's ten largest holdings make up 25% of its $3.07B portfolio in Q1 2021.
  • Rice Hall James & Associates opened 29 new positions and closed 14 in Q1 2021.
  • Rice Hall James & Associates's portfolio value rose 7.9% quarter-over-quarter to $3.07B.

Based on Rice Hall James & Associates's 13F filing for Q1 2021, filed 14 May 2021.